Meir Bialer

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 30

Top Topics

Randomized Controlled Trial

Pulmonary Embolism

Newly Diagnosed

Ejection Fraction

Top Venues

Clinical pharmacokinetics

This page only lists publications with an associated author ORCID identifier.

Publications

Rachel Goldstein, Natalie Rabkin, Noa Buchman, Aviya R Jacobs, Khaled Sandouka, Bruria Raccah, Tamar Fisher Negev, Ilan Matok, Meir Bialer, Mordechai Muszkat
The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations. CNS drugs (2024)
Meir Bialer, Svein I Johannessen, Matthias J Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H Steve White
Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development. Epilepsia (2024)
Rachel Goldstein, Natalie Rabkin, Noa Buchman, Aviya R Jacobs, Khaled Sandouka, Bruria Raccah, Tamar Fisher Negev, Ilan Matok, Meir Bialer, Mordechai Muszkat
The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations. CNS drugs 38 (5) (2024)
Rachel Goldstein, Natalie Rabkin, Noa Buchman, Aviya R Jacobs, Khaled Sandouka, Bruria Raccah, Tamar Fisher Negev, Ilan Matok, Meir Bialer, Mordechai Muszkat
The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations. CNS drugs 38 (5) (2024)
Rachel Goldstein, Natalie Rabkin, Noa Buchman, Aviya R Jacobs, Khaled Sandouka, Bruria Raccah, Tamar Fisher Negev, Ilan Matok, Meir Bialer, Mordechai Muszkat
The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations. CNS drugs 38 (5) (2024)
Rachel Goldstein, Natalie Rabkin, Noa Buchman, Aviya R Jacobs, Khaled Sandouka, Bruria Raccah, Tamar Fisher Negev, Ilan Matok, Meir Bialer, Mordechai Muszkat
The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations. CNS drugs 38 (5) (2024)
Meir Bialer, Svein I Johannessen, Matthias J Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H Steve White
Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development. Epilepsia (2024)
Rachel Goldstein, Natalie Rabkin, Noa Buchman, Aviya R Jacobs, Khaled Sandouka, Bruria Raccah, Tamar Fisher Negev, Ilan Matok, Meir Bialer, Mordechai Muszkat
The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations. CNS drugs 38 (5) (2024)
Rachel Goldstein, Natalie Rabkin, Noa Buchman, Aviya R Jacobs, Khaled Sandouka, Bruria Raccah, Tamar Fisher Negev, Ilan Matok, Meir Bialer, Mordechai Muszkat
The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations. CNS drugs 38 (5) (2024)
Rachel Goldstein, Aviya R Jacobs, Lana Zighan, Naomi Gronich, Meir Bialer, Mordechai Muszkat
Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment. CNS drugs (2023)
Emilio Perucca, Meir Bialer, H Steve White
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System. CNS drugs (2023)
Natalia Erenburg, Roa'a Hamed, Chanan Shaul, Emilio Perucca, Meir Bialer
Comparative Activity of the Enantiomers of Fenfluramine and Norfenfluramine in Rodent Seizure Models, and Relationship with their Concentrations in Plasma and Brain. Epilepsia (2023)
Rachel Goldstein, Aviya R Jacobs, Lana Zighan, Naomi Gronich, Meir Bialer, Mordechai Muszkat
Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment. CNS drugs 37 (3) (2023)
Rachel Goldstein, Aviya R Jacobs, Lana Zighan, Naomi Gronich, Meir Bialer, Mordechai Muszkat
Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment. CNS drugs 37 (3) (2023)
Rachel Goldstein, Aviya R Jacobs, Lana Zighan, Naomi Gronich, Meir Bialer, Mordechai Muszkat
Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment. CNS drugs 37 (3) (2023)
Emilio Perucca, H Steve White, Meir Bialer
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development. CNS drugs (2023)
Natalia Erenburg, Roa'a H S Yosief, Chanan Shaul, Dinorah Barasch, Emilio Perucca, Meir Bialer
Pharmacokinetics of d- and l-norfenfluramine following their administration as individual enantiomers in rats. Epilepsia (2023)
Meir Bialer, Emilio Perucca
Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine? CNS drugs 36 (2) (2022)
Chanan Shaul, Simcha Blotnick, Liat Adar, Mordechai Muszkat, Meir Bialer, Yoseph Caraco
Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance. Clinical pharmacokinetics 61 (8) (2022)
Meir Bialer, Svein I Johannessen, Matthias J Koepp, René H Levy, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H Steve White
Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II. Drugs in more advanced clinical development. Epilepsia 63 (11) (2022)
Maor Wanounou, Yoseph Caraco, René H Levy, Meir Bialer, Emilio Perucca
Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy. Clinical pharmacokinetics 61 (9) (2022)
Meir Bialer, Svein I Johannessen, Matthias J Koepp, René H Levy, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H Steve White
Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): I. Drugs in preclinical and early clinical development. Epilepsia 63 (11) (2022)
Valentina Franco, Pavel Gershkovich, Emilio Perucca, Meir Bialer
The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. Clinical pharmacokinetics 59 (12) (2021)
Reem Odi, Valentina Franco, Emilio Perucca, Meir Bialer
Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe. Epilepsia 62 (2) (2021)
Meir Bialer, Emilio Perucca
Response: Cannabidiol antiseizure activity and its interactions with clobazam: "It's déjà vu all over again" Yogi Berra. Epilepsia 61 (8) (2020)
Meir Bialer, Svein I Johannessen, Matthias J Koepp, René H Levy, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H Steve White
Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development. Epilepsia 61 (11) (2020)
Reem Odi, David Bibi, Travis Wager, Meir Bialer
A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs-From phenobarbital to cenobamate and beyond. Epilepsia 61 (8) (2020)
Meir Bialer, Svein I Johannessen, Matthias J Koepp, René H Levy, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H Steve White
Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development. Epilepsia 61 (11) (2020)
David Bibi, Meir Bialer
Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs-A CNS-active stereoisomer of SPD. Epilepsia 61 (1) (2020)
Meir Bialer, Emilio Perucca
Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. Epilepsia 61 (6) (2020)